A biomimetic nanovesicle derived from BCG-primed macrophages with mannose modification for targeted immunotherapy against cryptococcal meningitis
Authors:
- 2 January 2026
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 391, 114596
Abstract
No abstract availableKeywords
Funding Information
- Sichuan Provincial Administration of Traditional Chinese Medicine (2024MS149)
- Science and Technology Major Project of Guangxi (AA23073012)
- China Postdoctoral Science Foundation (2021M693953)
- National Natural Science Foundation of China (32060018)
- National Natural Science Foundation of China (32360035)
- National Natural Science Foundation of China (82472328)
- Sichuan Provincial Science and Technology Support Program (2025NSFSC2139)
This publication has 41 references indexed in Scilit:
- Development of molecular sensors based on fluorescent proteins for polarized macrophages identificationAnalytical Sciences, 2024
- Isobavachalcone: A redox antifungal agent impairs the mitochondria protein of Cryptococcus neoformansInternational Journal of Antimicrobial Agents, 2024
- Multifaceted therapeutic applications of biomimetic nanovaccinesDrug Discovery Today, 2024
- Macrophage membrane-camouflaged biomimetic nanovesicles for targeted treatment of arthritisAgeing Research Reviews, 2024
- Cell‐Based Biomaterials for Coronavirus Disease 2019 Prevention and TherapyAdvanced Healthcare Materials, 2023
- The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysisThe Lancet Infectious Diseases, 2022
- Macrophage Cell Membrane‐Cloaked Nanoplatforms for Biomedical ApplicationsSmall Methods, 2022
- Pharmacological review of isobavachalcone, a naturally occurring chalconePharmacological Research, 2021
- BCG Vaccination Induces Long-Term Functional Reprogramming of Human NeutrophilsCell Reports, 2020
- Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysisThe Lancet Infectious Diseases, 2017